» Articles » PMID: 7564669

Dopaminergic Defect of Enteric Nervous System in Parkinson's Disease Patients with Chronic Constipation

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1995 Sep 30
PMID 7564669
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical studies suggest that gut disorders are common in Parkinson's disease, but the morphological basis is unknown. Depletion of dopamine-containing neurons in the central nervous system is a basic defect in Parkinson's disease. We compared colonic tissue from 11 patients with advanced Parkinson's disease, 17 with adenocarcinoma (normal tissue was studied), and five who underwent colectomy for severe constipation. Immunohistochemistry was used to stain myenteric and submucosal neurons for dopamine, tyrosine hydroxylase, and vasoactive intestinal polypeptide (VIP). Each class of neurons was quantified as a percentage of the total neuronal population stained for the marker protein gene product 9.5. Nine of the 11 Parkinson's disease patients had substantially fewer dopaminergic myenteric neurons than the other subjects (mean 0.4 [SE 0.2] vs 6.9 [2.3] in controls and 5.7 [2.0] in constipated subjects). There was very little difference between the groups in numbers of tyrosine-hydroxylase and VIP neurons. Two Parkinson's disease patients had similar distributions of all types of neurons, including dopaminergic myenteric neurons, to the controls. High-performance liquid chromatography showed lower levels of dopamine in the muscularis externa (but not mucosa) in four Parkinson's disease patients than in four controls (7.3 [5.1] vs 24.2 [4.6] nmol per g protein), but levels of dopamine metabolites were similar in the two groups. The identification of this defect of dopaminergic neurons in the enteric nervous system in Parkinson's disease may lead to better treatment of colorectal dysfunction in this disease.

Citing Articles

The interrelationship between intestinal immune cells and enteric α-synuclein in the progression of Parkinson's disease.

Cheng Y, Chiang H Neurol Sci. 2025; .

PMID: 40085320 DOI: 10.1007/s10072-025-08114-w.


Assessment of gastrointestinal function and enteric nervous system changes over time in the A53T mouse model of Parkinson's disease.

Han M, Di Natale M, Lei E, Furness J, Finkelstein D, Hao M Acta Neuropathol Commun. 2025; 13(1):58.

PMID: 40075409 PMC: 11899089. DOI: 10.1186/s40478-025-01956-7.


Physical Activities and Parkinson's Disease Progression: A Two-Sample Mendelian Randomization Study.

Luo X, Xue C, Pan Y, Wei W, Hao Z, Liu Z CNS Neurosci Ther. 2025; 31(2):e70296.

PMID: 39992049 PMC: 11848732. DOI: 10.1111/cns.70296.


Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson's disease.

Zhang Y, Mo C, Ai P, He X, Xiao Q, Yang X Gut Microbes. 2025; 17(1):2454937.

PMID: 39875349 PMC: 11776486. DOI: 10.1080/19490976.2025.2454937.


Oral Trehalose Intake Modulates the Microbiota-Gut-Brain Axis and Is Neuroprotective in a Synucleinopathy Mouse Model.

Pradeloux S, Coulombe K, Ouamba A, Isenbrandt A, Calon F, Roy D Nutrients. 2024; 16(19).

PMID: 39408276 PMC: 11478413. DOI: 10.3390/nu16193309.